Neurosterix
Boston, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $63M
Overview
Developing neurosteroid-based therapies for CNS disorders like epilepsy and depression.
NeurosciencePsychiatry
Technology Platform
Proprietary platform for designing small molecule modulators of neurosteroid pathways and GABA-A receptors.
Funding History
1Total raised:$63M
Venture$63M
Opportunities
Large market for treatment-resistant CNS disorders with potential for first-in-class mechanisms.
Risk Factors
High clinical development risk in neuroscience and challenges in demonstrating clear efficacy endpoints.
Competitive Landscape
Faces competition from larger pharma in CNS but has a niche focus on neurosteroids with limited direct competitors.